Parsons Posts Loss, Slashes 2026 Outlook as It Reshapes Portfolio
Parsons shares crashed after a $15.2M Q2 loss and sharp cuts to 2026 revenue and EBITDA guidance from portfolio reshaping.
NOTRELOAD AI
Biogen Beats Q2 Estimates as Newer Drugs Drive Growth
Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%.
FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis
FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.
Garmin Raises Full-Year Outlook After Strong Wearables Demand in Q2
Garmin raises full-year targets to $8.05B revenue and $10 EPS after Q2 sales hit $2.02B, led by 25% fitness growth from wearables demand.
FDA Grants Priority Review to PolyPid’s D-PLEX100 for Surgical Infection Prevention
PDUFA date set for Nov 28, 2026, triggering $15M milestone.
Data Centers Power Generac’s Q2 Beat: Sales Up 11%, Margins Surge
Generac secures a second global supply deal with a hyperscale data center customer, lifting its backlog to $1.6B and powering strong Q2 growth.